clinical trial · NCT04486638
Dengvaxia US Pregnancy Registry
Sanofi Pasteur, a Sanofi Company·—·recruiting·n = 500
Dengue Virus InfectionDengue Tetravalent Vaccine, Live
brief summary
The primary objective of this study is to assess maternal, obstetrical, pregnancy, and neonatal and infant outcomes among women and their offspring(s) vaccinated with Dengvaxia during their pregnancy
started
Jan 1, 2023
primary completion
Jun 30, 2029
completion
Jun 30, 2029
last updated
Jan 21, 2026
detailed description
Exposed pregnant women will be followed up to the end of their pregnancy, and the offspring(s) will be followed up to 1 year of age.
official title
Dengvaxia US Pregnancy Registry: A Surveillance Study to Assess the Safety of Dengvaxia Among Exposed Pregnant Women and Their Offsprings (DNG00044)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol